Claris Lifesciences 2011 annual revenues at Rs738.77 crore

Claris Lifesciences’ consolidated profit after tax for the year 2011 stood at Rs126.26 crore with margins of 17.1%.

Claris Lifesciences, which announced its audited financial results for the year ended 31 December 2011, had consolidated annual revenues of Rs738.77 crore compared to Rs752.34 crore in the previous year. The break-up of the revenue between domestic and international sales was 47% and 53% respectively.

Consolidated EBITDA stood at Rs240.41 crore for the year 2011 with margins at 32.5% against Rs243.38 crore with margins of 32.4%. Consolidated profit after tax for the year 2011 stood at Rs126.26 crore with margins of 17.1% against Rs141.44 crore for the previous year with margins of 18.8%.

The Board of Directors has recommended a dividend of Rs2 per share (20%).

In the early afternoon, Claris Lifesciences was trading at around Rs150 per share on the Bombay Stock Exchange, 3.16% up from the previous close.

User

Glenmark Generics receives USFDA approval for two new drugs

Glenmark’s current portfolio consists of 76 products authorized for distribution in the US marketplace.

Glenmark Generics, USA, the subsidiary of Glenmark Generics has announced that they have been granted final approval for two abbreviated new drug approvals (ANDA’s) from the United States Food and Drug Administration (USFDA).

Today’s approvals are for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg. Glenmark will market this approved oral contraceptive as MarlissaTM Tablets and plan to commence shipping both products immediately.

Ciclopirox Gel 0.77%, is the generic version of Loprox Gel, 0.77%, of Medicis Pharmaceutical Corporation. Ciclopirox Gel is indicated for the topical treatment of seborrheic dermatitis of the scalp and is available in 30, 45, and 100 gram tube presentations. According to IMS Health sales data for the 12 month period ending September 2011, Ciclopirox Gel garnered annual sales of greater than USD 10 million. Marlissa Tablets are Glenmark’s generic version of Nordette tablets by Duramed Pharmaceuticals.

Marlissa tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. According to IMS Health for the 12 month period ending September 2011 total market sales achieved for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg were approximately USD 50.84 million. Today’s approval marks Glenmark’s eight female hormonal product authorized for distribution by the USFDA.

Glenmark’s current portfolio consists of 76 products authorized for distribution in the US marketplace. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

In the early afternoon, Glenmark Pharmaceuticals was trading at around Rs311.10 per share on the Bombay Stock Exchange, 0.94% up from the previous close.

User

Maruti Suzuki February sales rises 6.5% to 118,949 units

Domestic sales went up by 6% to 1,07,653 vehicles in February 2012 compared with same period last year.

Maruti Suzuki India announced a rise of 6.5% in sales to 118,949 vehicles in February 2012 led by strong exports growth. The company had sold a total of 111,645 vehicles in February 2011. This includes 11,296 units for export, a growth of 11.8%.

Domestic sales went up by 6% to 1,07,653 vehicles in February 2012 compared with same period last year.

In the early afternoon, Maruti Suzuki India was trading at around Rs1,305.15 per share on the Bombay Stock Exchange, 3.89% up from the previous close.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)